TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

Decera Clinical Education Oncology Podcast · Nov 18, 2025 · 20m

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan

TROP2 ADCS for patients with EGFR-mutated NSCLC

TIGIT-targeting agents: domvanalimab, rilvegostomig

Presenters:

Benjamin Levy, MD, FASCO

Associate Professor

Johns Hopkins School of Medicine

Clinical Director

Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)

Washington, DC

Alex Spira, MD, PhD, FASCO

Director…